Moderna Stock Is Climbing Thanks to Merck, But Is It Still a Buy?

On Dec. 14, Moderna (MRNA -1.93%) and Merck (MRK 0.73%) jointly reported some great news for patients as well as investors: A powerful new cancer therapy is in the works, and the freshly published mid-stage clinical trial data look favorable. Now, the biotech's shares are up by 21% over the last 30 days, and they likely have much further to run over the long term.But the coronavirus vaccine developer's stock actually lost a similar proportion of its value over the last three years, and its revenue is dramat ...